Solana Company Q2 FY2021 Earnings Call

· Earnings call transcript and AI-powered summary

Company Overview and Strategic Focus
  • Helius Medical Technologies is focused on the commercialization of its PoNS (Portable Neuromodulation Stimulator) device, which recently received its first U.S. FDA regulatory clearance for treatment of gait deficit due to Multiple Sclerosis (MS).
  • The company’s long-term value strategy revolves around U.S. market expansion, leveraging commercial insights from current operations in Canada.
Key Strategic Initiatives & Progress
  • Secured licensing to distribute PoNS in 43 U.S. states, aiming for near-complete national coverage by year-end to support a 2022 launch.
  • Strengthened leadership team with key appointments:
    • Fred Fantazzia, VP of Sales and Marketing, North America
    • Dr. Antonella Favit-Van Pelt, Chief Medical Officer
    • Dane Andreeff appointed as President and CEO
    • Jeff Mathiesen named as CFO
  • Targeting 130,000 MS patients in the U.S. initially, with commercialization focused on 10 states representing over 50% of that group.
  • Launched PoNS U.S. website to support awareness-building among physicians and patients.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Please standby. Good evening, ladies and gentlemen and welcome to the Second Quarter of Fiscal Year 2021 Earnings Conference Call for Helius Medical Technologies. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company’s website for replay shortly. Before we begin, I would like to remind everyone that our remarks and responses to your questions may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Such factors may be updated from time-to-time in our other filings with the SEC, which are available on our website. All statements may made during this call are as of August 12, 2021. We undertake no obligation to publicly update or revise our forward-looking statements, as a result of new information, future events or otherwise except as required by law. I would now like to turn the conference over to Mr. Dane Andreeff, Helius Medical’s President and Chief Executive Officer. Please go ahead, sir. Dane Andreeff: Great. Thank you, operator and my apologies, we had some technical difficulties, but welcome everyone to Helius Med

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional